share_log

Evome Sells Simbex R&D Business Unit to Riddell for $4.83M in Cash; Improves Balance Sheet, Reduces Biodex Acquisition Debt

Evome Sells Simbex R&D Business Unit to Riddell for $4.83M in Cash; Improves Balance Sheet, Reduces Biodex Acquisition Debt

Evome以483萬美元現金將Simbex研發業務部門出售給裏德爾;改善資產負債表,減少Biodex的收購債務
GlobeNewswire ·  04/02 23:18

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the "Company" or "Evome") (TSXV: EVMT) has reached an agreement with EB Sports Corp. (the "Buyer")‎, the parent company of Riddell Sports Group, an industry leader in football helmet technology and innovation, to sell Simbex LLC ("Simbex"), the Company's R&D business unit, for approximately $4.83M in cash. The proceeds will be used to pay down Simbex debt and reduce Evome's acquisition debt to the seller of its operating subsidiary Biodex Rehab Systems, LLC ("Biodex"), strengthening the Company's balance sheet, as well as increasing focus on revenue and profit growth from the Biodex product line.

紐約,2024年4月2日(環球新聞專線)——Evome Medical Technologies Inc.(“公司” 或 “Evome”)(多倫多證券交易所股票代碼:EVMT)已與足球頭盔技術和創新行業領導者裏德爾體育集團的母公司EB Sports Corp.(“買方”)‎ 達成協議,出售該公司的研發業務部門Simbex LLC(“Simbex”)大約483萬美元的現金。所得款項將用於償還Simbex債務,減少Evome對運營子公司Biodex Rehab Systems, LLC(“Biodex”)賣方的收購債務,加強公司的資產負債表,並越來越關注Biodex產品線的收入和利潤增長。

This focus on revenue growth and market expansion has led Biodex to launch a new, high-tech product called the RST (Reactive Step Trainer). The RST was launched by the Company at the American Physical Therapy Association Combined Sections Meeting in Boston on February 15, 2024. The RST is designed to improve balance and reduce tripping and falling, particularly among elderly patients. The Reactive Step Trainer can provide repetitive conditioning training along with random and on-demand perturbation challenges, designed to help patients improve their compensatory step strategies and reduce fall risk. It has been meticulously engineered to be cost-effective, ensuring accessibility to a wider range of patients, while also prioritizing functionality to effectively cater to the clinical requirements of Physical Therapists.

這種對收入增長和市場擴張的關注促使Biodex推出了一款名爲RST(反應式步進訓練器)的新型高科技產品。RST由公司於2024年2月15日在波士頓舉行的美國物理治療協會聯合分會會議上推出。RST 旨在改善平衡,減少絆倒和跌倒,尤其是在老年患者中。Reactive Step Trainer可以提供重複的體能訓練以及隨機和按需的擾動挑戰,旨在幫助患者改善補償步伐策略並降低跌倒風險。它經過精心設計,具有成本效益,可確保更廣泛的患者獲得服務,同時還優先考慮功能以有效滿足物理治療師的臨床需求。

Looking ahead, Evome plans to continue its innovation with the upcoming launch of the SpaceTek Knee in late 2024. This isokinetic device, co-developed with NASA, represents another milestone in Evome's commitment to advancing medical technology and improving patient outcomes while improving margins and increasing sales by democratizing its technology to a broader market.

展望未來,Evome計劃通過即將在2024年底推出SpaceTek Knee來繼續創新。這種等速設備是與美國宇航局共同開發的,是Evome致力於推進醫療技術和改善患者預後,同時通過將其技術普及到更廣泛的市場來提高利潤率和增加銷售額的又一個里程碑。

"Since July of 2023, I have worked tirelessly with our team to turn the company around" said Mike Seckler, CEO. "We started with a focus on increasing revenues and margins, which led to two consecutive quarters of positive Adjusted EBITDA. In the first quarter of the year we have focused on two strategic imperatives. First, we are reducing debt and improving our balance sheet by selling non-core business units. We will work towards continuing to make progress on our balance sheet in the second quarter. Second, we have retooled our production platform to deliver on increasing demand from our Biodex products. I believe that we have the potential to have a breakout second quarter of this year in terms of Biodex products and improvement of the balance sheet."

首席執行官邁克·塞克勒說:“自2023年7月以來,我一直在與我們的團隊孜孜不倦地合作,以扭轉公司的局面。”“我們一開始就專注於增加收入和利潤率,這使調整後的息稅折舊攤銷前利潤連續兩個季度實現正增長。今年第一季度,我們將重點放在兩個戰略當務之急上。首先,我們通過出售非核心業務部門來減少債務並改善資產負債表。我們將努力在第二季度繼續在資產負債表上取得進展。其次,我們重組了生產平台,以滿足對Biodex產品不斷增長的需求。我相信,就Biodex產品和資產負債表的改善而言,我們有可能在今年第二季度取得突破。”

Pursuant to a membership interest purchase agreement signed and dated April 1, 2024 between an indirect wholly owned subsidiary of the Company (the "Seller"), the Buyer and the Company, the Buyer has acquired all of the issued and outstanding capital stock of Simbex from the Seller in consideration for US$3,550,000 (approximately $4.83M) in cash. The gross proceeds will reduce senior debt of Simbex by US$824,441 upon closing and acquisition debt of the Evome associated with its acquisition of Biodex by US$2,115,559, with the remainder of funds used for transaction costs and debt reduction to subordinated and unsecured creditors.

根據公司間接全資子公司(“賣方”)、買方和公司於2024年4月1日簽署並於2024年4月1日簽署的會員權益購買協議,買方以355萬美元(約合483萬美元)的現金對價從賣方手中收購了Simbex的所有已發行和流通股本。總收益將使Simbex的優先債務減少824,441美元,此前與收購Biodex相關的Evome債務將減少2,115,559美元,其餘資金將用於交易成本和減免次級債權人和無擔保債權人的債務。

As a result of the sale, Evome expects a reduction in annual revenue of ~US$6,000,000. Net income is expected to decrease immaterially.

由於此次出售,Evome預計年收入將減少約6,000,000美元。預計淨收入將大幅減少。

Mike Seckler ‎
Chief Executive Officer ‎
Tel: 1 (800) 760-6826 ‎
Email: Info@Salonaglobal.com‎

邁克·塞克勒‎
首席執行官‎
電話:1 (800) 760-6826‎
電子郵件:Info@Salonaglobal.com‎

Cautionary Statements

警示聲明

Unless otherwise specified, all dollar amounts in this press release are expressed in Canadian ‎dollars.‎

除非另有說明,否則本新聞稿中的所有美元金額均以加拿大語‎dollars 表示。‎

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險投資交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Certain statements contained in this press release constitute "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. These statements can be identified by the use of forward-looking terminology such as "expects" "believes", "estimates", "may", "would", "could", ‎‎"should", "potential", ‎‎‎‎‎"will", "seek", "intend", "plan", and "anticipate", and similar expressions as they relate ‎‎‎‎to the Company, including: the Company launching new products in 2024 and the timing of such launches. All ‎statements ‎other than statements of ‎historical fact may be forward-looking‎ information. Such statements reflect the Company's current views and intentions with respect to future ‎events, and current information available to the Company, and are subject to certain risks, ‎uncertainties and assumptions, including, the Company having the necessary capital to complete its business objectives. The Company cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements. Such factors include but are not limited to the ‎‎general business and ‎‎economic ‎conditions in the regions in ‎which the Company operates; the ability of the Company to execute on key ‎‎priorities, ‎including the successful completion of acquisitions, business‎ retention, and‎‎ strategic plans and to‎‎ attract, develop ‎and retain key executives; difficulty integrating newly acquired businesses; ‎‎ongoing or new disruptions in the supply chain, the extent and scope of such supply chain disruptions, and the timing or extent of the resolution or improvement of such disruptions; the ability to‎‎‎ implement business strategies and pursue business opportunities; ‎‎disruptions in or attacks (including ‎cyber-attacks) on the Company's information technology, internet, network access or other ‎‎voice or data ‎communications systems or services; the evolution of various types of fraud or other ‎‎‎criminal behavior to which ‎ the Company is exposed; the failure of third parties to comply with their obligations to ‎‎ the Company or its ‎affiliates; the‎ impact of new and changes to, or application of, current laws and regulations; ‎granting of permits and licenses in a highly regulated business; the ‎overall difficult ‎‎‎‎‎litigation environment, including in the United States; increased competition; changes in foreign currency rates; ‎increased ‎‎‎‎funding ‎costs and market volatility due to market illiquidity and competition for funding; the ‎availability of funds ‎‎‎‎and resources to pursue operations; critical ‎accounting estimates and changes to accounting standards, policies,‎‎‎‎ and methods used by the Company; the occurrence of natural and unnatural‎‎ catastrophic ‎events ‎and claims ‎‎‎‎resulting from such events; as well as those risk factors discussed or ‎referred to ‎in the ‎Company's disclosure ‎documents filed with United States Securities and Exchange Commission ‎and ‎available at ‎www.sec.gov, and with ‎the securities regulatory authorities in certain provinces of Canada and ‎‎available at ‎. Should any ‎factor affect the Company in an unexpected manner, or should ‎‎assumptions underlying ‎the forward-looking ‎information prove incorrect, the actual results or events may differ ‎‎materially from the results ‎or events predicted. ‎Any such forward-looking information is expressly qualified in its ‎‎entirety by this cautionary ‎statement. Moreover, ‎the Company does not assume responsibility for the accuracy or ‎‎completeness of such ‎forward-looking ‎information. The forward-looking information included in this press release ‎‎is made as of the ‎date of this press ‎release and the Company undertakes no obligation to publicly update or revise ‎‎any forward-‎looking information, ‎other than as required by applicable law‎.

本新聞稿中包含的某些陳述構成1995年《私人證券訴訟改革法》和適用的加拿大證券法所指的 “前瞻性信息”。這些陳述可以通過使用前瞻性術語來識別,例如 “期望”,“相信”,“估計”,“可能”,”會”、“可以”、‎‎ “應該”、“潛在”、‎‎‎‎‎ “將”、“尋求”、“打算”、“計劃” 和 “預測”,以及相關的類似表達‎‎‎‎to 該公司,包括: 該公司在2024年推出新產品以及此類發佈的時間安排。 除‎historical 事實陳述外,所有‎statements‎other 都可能是前瞻性的‎ 信息。此類陳述反映了公司當前對未來‎events 的看法和意圖以及公司目前獲得的信息,並受某些風險、‎uncertainties 和假設的約束,包括公司擁有完成其業務目標所需的資本。公司警告說,此處包含的前瞻性陳述受重要因素的限制,這些因素可能導致實際業績與此類陳述所反映的業績存在重大差異。這些因素包括但不限於公司運營地區的‎‎general 業務和‎‎economic‎conditions;公司執行關鍵任務的能力‎which‎‎priorities,‎including 成功完成收購、業務‎ 保留和‎‎ 戰略計劃以及‎‎ 吸引、發展‎and 留住關鍵高管;難以整合新收購的業務;‎‎ongoing 或供應鏈出現新的中斷、此類供應鏈中斷的程度和範圍,以及解決或改善此類中斷的時機或程度;能力‎‎‎ 實施業務戰略並尋求商機;‎‎disruptions 對公司信息技術、互聯網、網絡接入或其他方面的攻擊(包括‎cyber-攻擊)‎‎voice 或數據‎communications 系統或服務;公司面臨的各種欺詐或其他‎‎‎criminal 行爲的演變;‎第三方未能履行其對‎‎ 公司或其‎affiliates 的義務;現行法律法規的新、變更或適用的‎ 影響;‎granting 在高度監管的企業中對許可證和執照的影響;‎overall 艱難‎‎‎‎‎litigation 環境,包括美國的環境;競爭加劇;外幣匯率的變化;‎increased‎‎‎‎funding‎costs 以及市場流動性不足和資金競爭導致的市場波動;基金的‎availability‎‎‎‎and 用於開展運營的資源;關鍵‎accounting 估計和會計準則、政策的變化,‎‎‎‎ 以及公司使用的方法;自然和非自然的發生‎‎ 災難性‎events‎and 索賠‎‎‎‎resulting 來自此類事件;以及所討論的風險因素或‎referred 至‎in 向美國證券交易委員會提交的披露‎documents‎Company‎and‎available 在‎www .sec.gov,還有加拿大某些省份的‎the 證券監管機構,‎‎available 位於‎。如果任何‎factor 以意想不到的方式影響公司,或者‎‎assumptions 標的‎the 前瞻性‎information 被證明不正確,則實際業績或事件可能會有所不同‎‎materially 來自結果‎or 事件的預測。‎Any 本警示詞在‎‎entirety 中對此類前瞻性信息進行了明確限定‎statement。此外,‎the Company 對這種外觀‎forward 的‎information 的準確性或‎‎completeness 不承擔任何責任。本新聞稿中包含的前瞻性信息‎‎is 截至本新聞稿‎date 發佈‎release 且公司沒有義務公開更新或修改‎‎any 向前發佈‎looking 信息,‎other 超出適用法律的要求‎。

This press release refers to "Adjusted EBITDA" which is a non-GAAP and non-IFRS financial ‎measure that does ‎not have a standardized meaning prescribed by GAAP or IFRS. "Adjusted EBITDA" is defined as net operating loss excluding depreciation of property and equipment, amortization ‎of right-of-use asset, amortization of intangible asset, severance expense due to restructuring, and stock-based ‎compensation‎.

本新聞稿提及 “調整後息稅折舊攤銷前利潤”,這是一項非公認會計准則和非國際財務報告準則財務‎measure,‎not 具有公認會計原則或國際財務報告準則規定的標準化含義。 “調整後息稅折舊攤銷前利潤” 定義爲淨營業虧損,不包括財產和設備折舊、攤銷‎of 使用權資產、無形資產攤銷、重組產生的遣散費用以及股票型‎compensation‎。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論